Choosing an antidepressant for a cardiac patient: escitalopram and amitriptyline lengthened QTc most

Design

IPD network meta-regression of double-blind RCTs, plus aggregate meta-analysis

Population

8,679 adults with major depression (QTc); 52,398 in 139 trials (events)

Primary outcome

QTc Fridericia change over eight weeks vs placebo

Effect

Escitalopram +8.7 ms (CrI 1.6 to 15.8); amitriptyline +5.3 ms (0.8 to 9.8); MACE RD 0.01%

An individual participant data network meta-regression in the BMJ (23 September 2026) harmonised QTc data from 35 double-blind trials (8,679 adults with major depression) comparing ten antidepressants with placebo over the first eight weeks, adjusting for baseline QTc, age, sex, BMI, potassium and eGFR. A separate pooled analysis of 139 trials (52,398 people) looked at early major cardiovascular events.

Against placebo, escitalopram lengthened QTc (Fridericia) by 8.7 ms (95% credible interval 1.6 to 15.8) and amitriptyline by 5.3 ms (0.8 to 9.8). Once risk factors were considered, amitriptyline and escitalopram were most often associated with the greatest prolongation; venlafaxine and vortioxetine with the least. Effects varied widely between individuals, especially with escitalopram, fluoxetine and mirtazapine. There was no excess of early cardiovascular events or non-suicidal death (risk difference 0.01%, −0.01% to 0.02%).

Trial populations exclude most patients with heart disease, and eight weeks is short, so the reassurance on events applies to relatively healthy adults. But the ranking is useful precisely where a cardiologist is asked: the patient with a long baseline QTc, low potassium or other QT-prolonging drugs.

For that patient, escitalopram and amitriptyline are the ones to avoid or monitor; for most others, the QT effect of antidepressants is modest and should not stop treatment.

• In a patient with a borderline QTc, low potassium or other QT-prolonging drugs, avoid escitalopram and amitriptyline where an alternative suits
• Venlafaxine and vortioxetine had the least QTc prolongation; sertraline was not among the ten analysed
• Repeat the ECG within a few weeks of starting escitalopram in a patient at arrhythmic risk
• Correct potassium and magnesium before starting any antidepressant in a cardiac patient
• Reassure psychiatric colleagues that most patients without cardiac risk factors do not need QT monitoring

Why it matters

It turns a vague 'watch the QT' into a drug-by-drug ranking a cardiologist can give when asked for advice.

Don't overread it

The trials excluded most cardiac patients and lasted eight weeks; absence of early events does not establish long-term safety in heart disease.

The statistics, in plain English

An 8.7 ms mean increase is small in most people, but the credible interval runs to 15.8 ms and individual responses varied widely, so in someone who already sits near the threshold it can matter. The event risk difference of 0.01% is essentially zero.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.